Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Not all myasthenia gravis (MG) therapies work the same way — and antibody status is a key reason why. Experts explain that FcRn inhibitors, complement inhibitors, and B-cell–depleting therapies each suit different antibody profiles, and that patient factors like age, pregnancy, and prior treatment response further shape the decision. There's no one-size-fits-all approach here.
When it comes to advanced therapy for myasthenia gravis (MG), antibody status isn't just a lab result — it's a roadmap. Experts highlight that acetylcholine receptor (AChR)-positive, MuSK-positive, LRP4-positive, and seronegative MG each have distinct biologies that make certain therapies more or less appropriate. For example, complement inhibition has a clear rationale in AChR-positive disease but is mechanistically less suited for MuSK-positive MG, where complement-independent pathways dominate.
Beyond antibody type, clinicians must weigh a range of patient-specific factors. Age, reproductive status, comorbidities, and concomitant medications all influence the risk-benefit calculus. Women of childbearing potential face particularly complex decisions, as pregnancy and preconception planning can narrow available options. Prior disease course matters too — patients who responded well to plasma exchange may be strong candidates for FcRn-targeted therapy, since both approaches reduce circulating pathogenic IgG.
Key Takeaways:
Why it matters: Selecting the wrong mechanism of action in MG isn't just ineffective — it can expose patients to unnecessary risks. A structured, biology-first approach to therapy selection can improve outcomes and reduce harm.
